|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:accessories
|
gptkb:U._S._government
due to demand
|
|
gptkbp:activities
|
neutralizes the virus
|
|
gptkbp:advocates_for
|
required for clinical trials
|
|
gptkbp:approves
|
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:availability
|
limited supply
|
|
gptkbp:can_be_used_with
|
gptkb:Etesevimab
|
|
gptkbp:clinical_trial
|
gptkb:United_States
gptkb:Eli_Lilly_and_Company
Phase 2
published in medical journals
Phase 3 ongoing
reduction in viral load
thousands enrolled
|
|
gptkbp:collaborations
|
gptkb:Research_Institute
academic institutions
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:distribution
|
available in multiple countries
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
single infusion
|
|
gptkbp:education
|
provided by healthcare providers
|
|
gptkbp:emergency_services
|
gptkb:2020
|
|
gptkbp:feedback
|
generally positive
|
|
gptkbp:future_plans
|
exploring combination therapies
|
|
gptkbp:healthcare
|
significant during pandemic
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lilly's COVID-19 antibody treatment
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
reduces hospitalization rates
|
|
gptkbp:is_monitored_by
|
required post-administration
|
|
gptkbp:is_used_for
|
treating COVID-19
|
|
gptkbp:launch_date
|
November 2020
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Bamlanivimab
|
|
gptkbp:pharmacokinetics
|
monoclonal antibody half-life
|
|
gptkbp:population
|
high-risk patients
|
|
gptkbp:price
|
varies by provider
|
|
gptkbp:provides_information_on
|
updated regularly
CDC recommendations
|
|
gptkbp:publishes
|
peer-reviewed articles
|
|
gptkbp:receives_funding_from
|
government and private sources
|
|
gptkbp:regulatory_compliance
|
international agencies
|
|
gptkbp:research_focus
|
COVID-19 variants
|
|
gptkbp:safety_features
|
adverse event reporting
generally well tolerated
|
|
gptkbp:setting
|
outpatient setting
|
|
gptkbp:side_effect
|
allergic reactions
reduces burden on hospitals
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:student_enrollment
|
age 12 and older
|
|
gptkbp:supply_chain
|
managed by Eli Lilly
|
|
gptkbp:targets
|
SARS-Co V-2 virus
|
|
gptkbp:training
|
required for administration
|
|
gptkbp:treatment
|
improved recovery times
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:type_of_insurance
|
varies by plan
|